| Literature DB >> 33328988 |
Bernát Nógrádi1,2, Ádám Nyúl-Tóth1,3, Mihály Kozma1,4, Kinga Molnár1,4, Roland Patai1, László Siklós1, Imola Wilhelm1,5, István A Krizbai1,5.
Abstract
Neuronal injuries are accompanied by release and accumulation of damage-associated molecules, which in turn may contribute to activation of the immune system. Since a wide range of danger signals (including endogenous ones) are detected by the nucleotide-binding oligomerization domain-, LRR- and pyrin domain-containing protein 3 (NLRP3) pattern recognition receptor, we hypothesized that NLRP3 may become activated in response to motor neuron injury. Here we show that peripheral injury of the oculomotor and the hypoglossal nerves results in upregulation of NLRP3 in corresponding motor nuclei in the brainstem of mice. Although basal expression of NLRP3 was observed in microglia, astroglia and neurons as well, its upregulation and co-localization with apoptosis-associated speck-like protein containing a caspase activation and recruitment domain, suggesting inflammasome activation, was only detected in neurons. Consequently, increased production of active pro-inflammatory cytokines interleukin-1β and interleukin-18 were detected after hypoglossal nerve axotomy. Injury-sensitive hypoglossal neurons responded with a more pronounced NLRP3 upregulation than injury-resistant motor neurons of the oculomotor nucleus. We further demonstrated that the mitochondrial protector diazoxide was able to reduce NLRP3 upregulation in a post-operative treatment paradigm. Our results indicate that NLRP3 is activated in motoneurons following acute nerve injury. Blockade of NLRP3 activation might contribute to the previously observed anti-inflammatory and neuroprotective effects of diazoxide.Entities:
Keywords: acute nerve injury; diazoxide; inflammasome; motor neuron; neuroinflammation; nucleotide-binding oligomerization domain-, LRR- and pyrin domain-containing protein 3
Year: 2020 PMID: 33328988 PMCID: PMC7732612 DOI: 10.3389/fphar.2020.584184
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Antibodies used for IHC, IF and WB.
| Stainings | Primary antibodies | Secondary antibodies |
|---|---|---|
| NLRP3 (IHC) | Polyclonal goat against | Biotinylated rabbit anti-goat IgG antibody (H + L), 1:800 (BA-5000, Vector Laboratories) |
| ASC (IHC) | Monoclonal mouse against | Biotinylated goat anti-mouse IgG antibody (H + L), 1:800 (BA-5000, Vector Laboratories) |
| NLRP3, NeuN (IF) and hoechst | Anti- | Alexa Fluor® 488 cross-adsorbed donkey anti-goat IgG, 1:500 (A-11055, Thermo Fisher Scientific) |
| Polyclonal mouse against | Cy™5 AffiniPure donkey anti-mouse IgG (H + L), 1:500 (715–175-150, Jackson Immunoresearch) | |
| NLRP3, ChAT (IF) and hoechst | Anti- | Cy™3 AffiniPure donkey anti-goat IgG (H + L), 1:500 (705–165-003, Jackson Immunoresearch) |
| Polyclonal rabbit against | Alexa Fluor® 488 AffiniPure donkey anti-rabbit IgG (H + L), 1:500 (711–545-152, Jackson Immunoresearch) | |
| NLRP3, GFAP (IF) and hoechst | Anti- | Alexa Fluor® 488 donkey anti-goat IgG (H + L), 1:500 |
| Polyclonal rabbit against | Alexa Fluor® 546 highly cross-adsorbed donkey anti-rabbit IgG (H + L), 1:500 (A-10040, Thermo Fisher Scientific) | |
| NLRP3, IBA1 (IF) and hoechst | Polyclonal goat against | Alexa Fluor® 488 donkey anti-goat IgG (H + L), 1:500 |
| Polyclonal rabbit against | Alexa Fluor® 546 donkey anti-rabbit IgG, 1:500 | |
| NLRP3 and AQP4 (IF) | anti- | Cy™3 donkey anti-goat IgG (H + L), 1:500 |
| Polyclonal rabbit against | Alexa Fluor® 647 AffiniPure donkey anti-rabbit IgG (H + L), 1:500 (711-605-152, Jackson Immunoresearch) | |
| NLRP3, GFAP and ASC (IF) | Anti- | Alexa Fluor® 488 cross-adsorbed donkey anti-goat IgG, 1:500 (A-11055, Thermo Fisher Scientific) |
| Anti- | Alexa Fluor® 546 donkey anti-rabbit IgG, 1:500 | |
| Anti- | Cy™5 donkey anti-mouse IgG, 1:500 | |
| IL-1β (WB) | Polyclonal goat against | HRP-conjugated rabbit anti-goat IgG (H + L), 1:4,000 (A5420, Sigma-Aldrich) |
| IL-18 (WB) | Polyclonal rabbit against | HRP-conjugated goat anti-rabbit IgG (H + L), 1:4,000 (111–035-003, Jackson Immunoresearch) |
| β-actin (WB) | Monoclonal mouse against | HRP-conjugated goat anti-mouse IgG (H + L), 1:4,000 (115–035-003, Jackson Immunoresearch) |
NLRP3, nucleotide-binding oligomerization domain-, LRR- and pyrin domain-containing protein 3; ASC, apoptosis-associated speck-like protein containing a caspase activation and recruitment domain; IF, immunofluorescence; IHC, immunohistochemistry; WB, western blot; IL-1β; interleukin-1 beta; IL-18, interleukin-18; GFAP, glial fibrillary acidic protein.
FIGURE 1Nucleotide-binding oligomerization domain-, LRR- and pyrin domain-containing protein 3 (NLRP3) protein expression in motor neurons of the oculomotor and hypoglossal nuclei after specific nerve axotomy. (A) Representative immunohistochemistry stainings of NLRP3 protein on Balb/c mouse brain sections from the anatomical region of the oculomotor (top panel) and the hypoglossal (bottom panel) nuclei (scale: 100 µm). Corresponding brain nerves were axotomized. (B) Representative fluorescence immunostaining images of NLRP3, neuronal nuclei (top panel) and choline acetyltransferase (bottom panel) proteins on Balb/c mouse brain sections from the anatomical region of hypoglossal nucleus after corresponding brain nerve axotomy (scale: 100 µm). Nuclei were counterstained with Hoechst 33342.
FIGURE 2Partial co-localization of nucleotide-binding oligomerization domain-, LRR- and pyrin domain-containing protein 3 (NLRP3) with glial marker proteins but not with microvessels on the injured side. (A) Representative confocal super-resolution microscopy (STED) images from fluorescent immunostaining of NLRP3 and ionized calcium-binding adapter molecule 1 proteins on Balb/c mouse brain sections from the anatomical region of the hypoglossal nucleus after corresponding brain nerve axotomy. Nuclei were counterstained with Hoechst 33342. Top panels: lower magnification (scale: 100 µm); bottom panels: high magnification (scale: 10 µm). (B) Representative confocal STED images from fluorescent immunostaining of NLRP3 and glial fibrillary acidic protein proteins on Balb/c mouse brain sections from the anatomical region of the hypoglossal nucleus after similar brain nerve axotomy. Nuclei were counterstained with Hoechst 33342. Top panels: lower magnification (scale: 100 µm); bottom panels: high magnification (scale: 10 µm). (C) Representative confocal STED images from fluorescent immunostaining of NLRP3 and aquaporin-4 proteins on Balb/c mouse brain sections from the anatomical region of the hypoglossal nucleus after similar brain nerve axotomy. Top panels: lower magnification (scale: 20 µm); bottom panels: high magnification (scale: 5 µm). Arrows indicate co-localization of signals.
FIGURE 3NLRP3 translocation from neuronal cell nuclei into the cytoplasm in response to XII. nerve axotomy. (A) Representative super-resolution microscopy [nucleotide-binding oligomerization domain-, LRR- and pyrin domain-containing protein 3 (NLRP3)] and confocal (ChAT) images on Balb/c mouse brain sections from the anatomical region of the hypoglossal nucleus from the non-operated and operated side after hypoglossal nerve axotomy. Top panels (on both the non-operated and operated sides): lower magnification (scale: 10 µm); bottom panels: high magnification (scale: 5 µm). (B) Representative immunohistochemistry staining images of NLRP3 protein on Balb/c mouse brain sections from the anatomical region of the hypoglossal nucleus, from the non-operated (left panel) and operated (right panel) sides after equivalent nerve axotomy (scale: 25 µm). (C) Quantification of intracellular distribution of NRLP3 staining in neurons from non-operated and operated sides of the hypoglossal nucleus. The graph shows average % ± SEM of neurons in which NLRP3 localized in the nucleus or the cytoplasm (n = 5 animals/group, *** = p < 0.0005).
FIGURE 4Co-localization of inflammasome components and production of active interleukin-1 beta (IL-1β) and IL-18 (IL-18) in the XII. nucleus. A) Representative immunohistochemistry staining images of apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC) protein on Balb/c mouse brain sections from the anatomical region of the hypoglossal nucleus after corresponding brain nerve axotomy (scale: 100 µm). (B) Representative confocal [nucleotide-binding oligomerization domain-, LRR- and pyrin domain-containing protein 3 (NLRP3)] and super-resolution microscopy (STED) (ASC) images on Balb/c mouse brain sections from the anatomical region of the hypoglossal nucleus after hypoglossal nerve axotomy (scale: 10 µm). Solid arrows indicate the co-localization of NLRP3 and ASC. Dashed arrows indicate NLRP3 without co-localization with ASC. (C) Representative confocal [NLRP3 and glial fibrillary acidic protein (GFAP)] and STED (ASC) images on Balb/c mouse brain sections from the anatomical region of the hypoglossal nucleus after corresponding brain nerve axotomy (scale: 10 µm). Solid arrows indicate co-localization of NLRP3 and ASC in the nucleus and cytoplasm of the cells. Dashed arrow indicates co-localization of NLRP3 with GFAP, but not with ASC. (D) Representative western blot images of IL-1β and IL-18 proteins in of the hypoglossal nuclei after unilateral axotomy of corresponding brain nerve. Arrows indicate pro-forms, arrowheads show active cytokines. (E) Quantification of pro- and active IL-1β expression based on the western blot analysis of the hypoglossal nuclei in n = 3 animals. The graph shows values normalized to β-actin levels and to control side (average ± SEM,* = p < 0.05; *** = p < 0.0005). (F) Quantification of active IL-18 expression based on the western blot analysis of the hypoglossal nuclei in n = 3 animals. The graph shows values normalized to β-actin levels and to control side (average % ± SEM, * = p < 0.05).
FIGURE 5Effect of diazoxide on nucleotide-binding oligomerization domain-, LRR- and pyrin domain-containing protein 3 (NLRP3) protein expression in hypoglossal nucleus. (A) Representative immunohistochemical staining images of NLRP3 protein on Balb/c mouse brain sections from the anatomical region of the hypoglossal nucleus after axotomy and treatment with either vehicle [dimethyl sulfoxide (DMSO)] or diazoxide (DZX) each day for 4 days after surgery (scale: 100 µm). (B) Quantitative analysis of NLRP3 protein expression in the oculomotor (n = 4) and in the hypoglossal (n = 4) nuclei after corresponding nerve axotomy. Hypoglossal nerve axotomized mice were treated with either vehicle (DMSO; n = 3) or diazoxide (n = 4) each day for 4 days after surgery. Graph represents the relative difference in the staining area fraction (average % ± SEM) of the operated side compared to the non-operated side of the nuclei (* = p < 0.05; *** = p < 0.0005).